Neuren Pharmaceuticals Ltd (NEU) - Total Assets
Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) holds total assets worth AU$331.25 Million AUD (≈ $234.38 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Neuren Pharmaceuticals Ltd (NEU) net assets for net asset value and shareholders' equity analysis.
Neuren Pharmaceuticals Ltd - Total Assets Trend (2000–2024)
This chart illustrates how Neuren Pharmaceuticals Ltd's total assets have evolved over time, based on quarterly financial data.
Neuren Pharmaceuticals Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Neuren Pharmaceuticals Ltd's total assets of AU$331.25 Million consist of 97.5% current assets and 2.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0.8% |
| Accounts Receivable | AU$172.91 Million | 42.2% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$31.00K | 0.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2000–2024)
This chart illustrates how Neuren Pharmaceuticals Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Neuren Pharmaceuticals Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuren Pharmaceuticals Ltd's current assets represent 97.5% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 89.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 42.2% of total assets.
Neuren Pharmaceuticals Ltd Competitors by Total Assets
Key competitors of Neuren Pharmaceuticals Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €1.30 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.69 Billion |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098
|
China | CN¥1.56 Billion |
Neuren Pharmaceuticals Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 40.42 | 25.42 | 16.11 |
| Quick Ratio | 40.42 | 25.42 | 16.11 |
| Cash Ratio | 0.75 | 0.29 | 15.26 |
| Working Capital | AU$312.32 Million | AU$219.07 Million | AU$9.08 Million |
Neuren Pharmaceuticals Ltd - Advanced Valuation Insights
This section examines the relationship between Neuren Pharmaceuticals Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.29 |
| Latest Market Cap to Assets Ratio | 2.72 |
| Asset Growth Rate (YoY) | 65.2% |
| Total Assets | AU$409.71 Million |
| Market Capitalization | $1.12 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Neuren Pharmaceuticals Ltd's assets at a significant premium (2.72x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Neuren Pharmaceuticals Ltd's assets grew by 65.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuren Pharmaceuticals Ltd (2000–2024)
The table below shows the annual total assets of Neuren Pharmaceuticals Ltd from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | AU$409.71 Million ≈ $289.89 Million |
+65.22% |
| 2023-12-31 | AU$247.97 Million ≈ $175.45 Million |
+473.12% |
| 2022-12-31 | AU$43.27 Million ≈ $30.61 Million |
+8.02% |
| 2021-12-31 | AU$40.06 Million ≈ $28.34 Million |
+60.53% |
| 2020-12-31 | AU$24.95 Million ≈ $17.66 Million |
+73.21% |
| 2019-12-31 | AU$14.41 Million ≈ $10.19 Million |
-45.93% |
| 2018-12-31 | AU$26.64 Million ≈ $18.85 Million |
+48.47% |
| 2017-12-31 | AU$17.94 Million ≈ $12.70 Million |
+188.95% |
| 2016-12-31 | AU$6.21 Million ≈ $4.39 Million |
-63.26% |
| 2015-12-31 | AU$16.90 Million ≈ $11.96 Million |
-23.53% |
| 2014-12-31 | AU$22.11 Million ≈ $15.64 Million |
-16.31% |
| 2013-12-31 | AU$26.41 Million ≈ $18.69 Million |
+211.41% |
| 2012-12-31 | AU$8.48 Million ≈ $6.00 Million |
-23.84% |
| 2011-12-31 | AU$11.14 Million ≈ $7.88 Million |
+94.79% |
| 2010-12-31 | AU$5.72 Million ≈ $4.05 Million |
-44.41% |
| 2009-12-31 | AU$10.28 Million ≈ $7.28 Million |
+20.37% |
| 2008-12-31 | AU$8.54 Million ≈ $6.05 Million |
-41.42% |
| 2007-12-31 | AU$14.59 Million ≈ $10.32 Million |
-25.29% |
| 2006-12-31 | AU$19.52 Million ≈ $13.81 Million |
-44.54% |
| 2005-12-31 | AU$35.20 Million ≈ $24.91 Million |
+171.60% |
| 2004-12-31 | AU$12.96 Million ≈ $9.17 Million |
+1762.35% |
| 2003-12-31 | AU$696.00K ≈ $492.46K |
-79.11% |
| 2002-12-31 | AU$3.33 Million ≈ $2.36 Million |
-35.29% |
| 2001-12-31 | AU$5.15 Million ≈ $3.64 Million |
+12.33% |
| 2000-12-31 | AU$4.58 Million ≈ $3.24 Million |
-- |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more